The role of IL-17 and IL-17-producing CD4 + T cells in acute graft-versus-host disease (GVHD) has been controversial in recent mouse and human studies. We carried out studies in a murine acute GVHD model of fully major histocompatibility complex-mismatched myeloablative bone marrow transplantation. We showed that donor wild-type CD4 + T cells exacerbated acute GVHD compared with IL-17 − / − CD4 + T cells, while IL-17 reduced the severity of acute GVHD. The augmentation of acute GVHD by transferred donor IL-17-producing CD4 + T cells was associated with increased Th1 responses, while IL-17 decreased the percentages of Th1 cells in the GVHD target organs. Furthermore, IL-17 reduced the infiltration of macrophages into the GVHD tissues. In vitro study showed that IL-17 could downregulate Th1 responses, possibly through inhibiting IL-12 production by donor macrophages. Depletion of macrophages in vivo diminished the protective effect of IL-17. Our results demonstrated the differential roles of adoptively transferred donor IL-17-producing CD4 + T cells and IL-17 in the same acute GVHD model.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for the treatment of hematological malignant diseases. However, serious complications of allo-HSCT, such as graft-versus-host disease (GVHD), affect the outcome of allo-HSCT and limit its applicability. 1 GVHD is the result of alloreactive donor T cells activated by host antigenpresenting cells and the initiation of a cascade of events that eventually leads to tissue damage in GVHD target organs, such as the liver, lungs, intestines and skin. 2 Previous studies demonstrated that the polarization of donor T cells toward the Th1 or Th2 phenotype is involved in the pathogenesis of GVHD. Th1 cells are considered the primary T helper subset to induce GVHD, and Th1 cytokines have been shown to contribute to the pathogenesis of GVHD. 3, 4 On the other hand, Th2 cytokines are able to inhibit Th1 responses and can delay or prevent GVHD. 5, 6 Th17 cells are a newly identified T-cell subset that mainly produces the proinflammatory cytokine IL-17A. In addition to IL-17A, Th17 cells produce high levels of IL-17F, IL-21 and IL-22, which can induce tissue inflammation and autoimmune diseases alone or in cooperation with other proinflammatory 1 cytokines. 7 Previous studies have clearly shown that IL-17A and Th17 cells have crucial roles in triggering inflammation and tissue injuries in autoimmune diseases, and are implicated in the pathophysiology of acute GVHD. However, the role of IL-17A and Th17 cells in acute GVHD has been controversial in recent mouse and human transplantation studies. The first study by Yi et al., 8 using IL-17A knockout donors, suggested that the absence of donor Th17 cells led to augmented acute GVHD due to enhanced Th1 differentiation and that neutralizing IL-17A might augment acute GVHD in a nonmyeloablative allogeneic BMT model. However, a following study by Kappel et al., 9 using the same mouse strain combinations but a myeloablative allogeneic BMT model demonstrated that IL-17A was dispensable for GVHD and GVT activity but contributed to the early development of CD4-mediated GVHD by promoting the production of proinflammatory cytokines, which recruited Th1 cells to lymphoid organs during the early phase after transplantation. Moreover, Carlson et al. 10 demonstrated that in vitro-differentiated Th17 cells generated substantial cutaneous and pulmonary pathology in murine models of acute GVHD. A subsequent report provided evidence that the Th17 subset alone was sufficient, but not necessary, for the development of GVHD. 11 Using RAR-related orphan receptor gamma (ROR)C − / − donor T cells, Fulton et al. 12 found that CD4 + T-cell expression of RORC is important in the pathogenesis of acute GVHD. However, in a fully major histocompatibility complex (MHC)-mismatched BMT model, T cells deficient in ROR-γt could induce GVHD as well as WT T cells. 13 T cells with a combined deficiency in ROR-γt and T-bet failed to induce GVHD, suggesting that both Th1 and Th17 responses may be required for GVHD pathogenesis. 13 Studies by our group and others on clinical allo-HSCT recipients demonstrated that acute GVHD patients had higher percentages of Th17 cells, [14] [15] [16] indicating that Th17 cells may contribute to the induction of acute GVHD. However, two other groups found no correlation between Th17 cells and skin or GI tract GVHD. 17, 18 Therefore, the precise role of IL-17 and Th17 cells in the development of acute GVHD needs to be further characterized.
In the current study, we attempted to clarify the roles of IL-17 and IL-17-producing CD4 + T cells in acute GVHD pathogenesis in the same animal model. We found that adoptively transferred donor IL-17-producing CD4 + T cells facilitated Th1 responses, which contributed to the development of acute GVHD. Meanwhile, IL-17 could alleviate acute GVHD by suppressing Th1 responses through modulating cytokine production by donor macrophages.
MATERIALS AND METHODS

Mice
Male C57BL/6 (WT) (H-2 b , CD45.2) and female BALB/C (H-2 d ) mice were purchased from Shanghai Laboratory Animal Center (Shanghai, China). IL-17 − / − C57BL/6 mice were kindly provided by Dr Chen Dong (Tsinghua University School of Medicine, Beijing, China). Male C57BL/6 (H-2 b , CD45.1) mice were purchased from Vital River Animal Technology Co. Ltd (Beijing, China). All mice were maintained in a specific pathogen-free room at the research animal facilities of Soochow University. Mice at 8-12 weeks of age were used in the experiments. Experiments were carried out and approved according to the guidelines of the Animal Care and Use Committee at Soochow University.
BMT and assessment of GVHD BALB/c mice were given 850 cGy (one dose) lethal total body irradiation from 60 Co on day − 1. The irradiated BALB/c mice were transplanted with 1 × 10 7 WT C57BL/6 T-cell-depleted BM (TCD-BM) and 5 × 10 6 WT C57BL/6 spleen cells (WT donor cells) or with 1 × 10 7 IL-17 − / − C57BL/6 TCD-BM and 5 × 10 6 IL-17 − / − C57BL/6 spleen cells (IL-17 − / − donor cells). In some experiments, irradiated BALB/c mice were transplanted with IL-17 − / − donor cells and injected with mouse recombinant IL-17 (rmIL-17, PeproTech, Rocky Hill, NJ, USA) at a dose of 1 μg/mouse or phosphate-buffered saline (PBS) or with anti-IL-12 p40 antibody (Sungene Biotech, Tianjin, China) at a dose of 200 μg/mouse on days 0 and 7 post BMT. To deplete macrophages, the mice were injected i.p. with 200 μl of liposomal clodronate or control liposomes (FormuMax Scientific Inc., CA, USA) on days 1 and 7 after BMT. For the adoptive transfer experiments, the CD4 + T or CD8 + T cells were sorted from splenocytes of WT donors or IL-17 − / − donors (⩾96% pure) using EasySep positive bead selection (Stem Cell Technologies, Vancouver, BC, Canada). TCD-BM cells (5 × 10 6 ) with WT or IL-17 − / − CD4 + T cells (0.5 × 10 6 ) plus WT or IL-17 − / − CD8 + T cells (0.5 × 10 6 ) were injected intravenously. The recipients were monitored daily for survival and every 5 days for body weight changes and clinical signs of GVHD. The clinical scoring was based on five parameters, as described previously. 19 
Cell preparation
The procedure for isolating single-cell suspensions from the bone marrow, spleens and livers from recipient mice has been described previously. 20, 21 Isolation of lymphocytes from small intestines and colonic tissues was according to the methods described previously. 22, 23 For isolating lung lymphocytes, lung tissues were minced finely and incubated in RPMI 1640 with 5% fetal calf serum containing 20 U/ml collagenase D and 1 μg/ml DNase. After incubation for 60 min at 37°C, the cells were collected by centrifugation. The cells were then suspended in 40% Percoll and layered onto 70% Percoll. Cells at the interface were then collected for further analysis. Cytometric bead array Twelve days after transplantation, blood samples were obtained from recipients via orbital veins and clotted on ice for 10 min, and serum was separated by centrifugation at 4°C and was stored at − 80°C for further analysis of IL-4, IL-6, IFN-γ, TNF-α, IL-17 and IL-10 using a cytometric bead array (CBA) kit according to the manufacturer's instructions (BD Biosciences).
Histopathologic analysis of the liver, lung, small intestine and skin Twelve days after transplantation, the livers, lungs, small intestines, colons and skin were obtained from the recipients and fixed in 10% neutral-buffered formalin. The samples were then embedded in paraffin, and 5-μm-thick sections were stained with H&E according to the standard protocols. All slides were read by an expert pathologist in a blinded manner. The images were visualized with an Olympus BX45 microscope. Image acquisition was performed with a Nikon Eclipse E400 and the accompanying software package. Tissue damage was assessed based on a semi-quantitative scoring system, as described previously. 24, 25 The means plus or minus the standard error of the scores of five recipients are shown for each group.
Immunohistochemistry
Twelve days after transplantation, the livers, lungs and small intestines were obtained from the recipients and fixed in 10% neutral-buffered formalin. The samples were then embedded in paraffin, and 5-μm-thick sections were obtained. The sections were subjected to immunohistochemical staining for macrophages using an antibody to CD11b (eBioscience) in the target tissues. Briefly, paraffin sections were dewaxed and hydrated before heat-mediated antigen retrieval. The endogenous peroxidase was blocked by incubation with 3% hydrogen peroxide solution in methanol, and non-specific binding sites were blocked with blocking serum. After incubation with the primary antibodies at 4°C overnight, secondary antibodies were added and incubated with the samples at room temperature for 20 min. Negative controls were performed by omitting the primary antibodies. The images were visualized with an Olympus BX45 microscope. Image acquisition was performed with Nikon Eclipse E400 and the accompanying software package. In some experiments, 10 μg/ml IL-17 mAbs, 10 μg/ml IL-12 mAbs, 10 μg/ml IFN-γ mAbs (all from eBioscience) or 100 ng/ml rmIL-17 (PeproTech, Rocky Hill, NJ, USA) were added.
Statistical analysis
Kaplan-Meier survival curves were generated using GraphPad Prism version 5 (GraphPad, San Diego, CA, USA). Significant differences in animal survival were analyzed by the log-rank test. Comparison of two means was performed using an unpaired two-tailed Student's test, and differences were considered statistically significant when Po0.05. The significance levels are marked *Po0.05; **Po0.01; ***Po0.001. Figures 1c and d) . The mice that received IL-17 − / − BM and splenocytes had accelerated GVHD mortality compared with those that received WT BM and splenocytes (Figure 1c) . The severity of GVHD in the mice that received WT BM/IL-17 − / − splenocytes or the mice that received IL-17 − / − BM/WT splenocytes was between those of the WT and IL-17 − / − donor groups when the combined phenotypes of survival, weight loss and clinical scores were considered (Figures 1c and d) . Both of these groups showed significantly less severe GVHD compared with the IL-17 − / − donor group, suggesting that IL-17 from either BM-derived cells or splenocytes had a protective effect in GVHD.
RESULTS
Adoptively transferred donor
In addition, we compared the histopathology of the livers, lungs, small intestines and skin harvested from the recipients 12 days post transplantation. Compared with the recipients of IL-17 − / − CD4 + donor T cells, the recipients of WT CD4 + T cells showed much more severe tissue damage and higher histopathology scores in the livers, lungs, small intestines and skin (Figures 1e and f) , which was in agreement with the results of the survival outcomes and clinical scores. Among the recipients of WT or IL-17 − / − donor cells, the most severe tissue lesions were found in the recipients of IL-17 − / − donors, which is consistent with this group having the shortest survival time and the highest clinical scores (Figures 1g and h ). Taken together, these results indicated that adoptively transferred donor IL-17-producing CD4 + T cells aggravated, while IL-17 alleviated, acute GVHD. (Figure 2c ). The transcription factors Tbet, GATA3 and ROR-γt were also examined to confirm that the Th1 response was significantly elevated in the GVHD target organs of the recipients of WT CD4 + T cells (Figure 2d) . Interestingly, most of the IL-17-producing cells were also IFN-γ-positive, indicating that the Th17 cells were highly plastic and that the IL-17-producing cell subset may be converted to IL-17/IFN-γ double-producing cells.
To address whether the difference in the Th1 response was derived from the transferred CD4 + T cells or the BM-derived donor T cells, irradiated BALB/c mice were transplanted with 5 × 10 6 B6 TCD-BM (from CD45.1 mice) and 0.5 × 10 6 WT B6 CD4 + T cells or with 0.5 × 10 6 IL-17 − / − B6 CD4 + T cells (from CD45.2 mice). As shown in Figure 2e , enhanced Th1 induction was only observed between the transferred donor WT CD4 + T cells and IL-17 − / − CD4 + T cells in the spleens, lungs and IELs. No significant differences were found in donor BM-derived IFN-γ-producing cells from the two groups (Figure 2f ). These results suggested that transferred IL-17-producing CD4 + T cells could be converted to produce IFN-γ, which contributed to the induction of acute GVHD.
Furthermore, we examined the serum levels of IL-2, IL-4, IL-6, IFN-γ, TNF-α and IL-10 in the recipients (Figure 2g ). We found that compared with the recipients of IL-17 − / − CD4 + T cells, the serum levels of both IL-6 and IFN-γ were significantly elevated (Po0.05) in the recipients of WT CD4 + T cells (Figure 2g ). The serum level of TNF-α was also increased in the recipients of WT CD4 + T cells compared with that of the IL-17 − / − CD4 + T-cell recipients, but the difference was not statistically significant. These data demonstrated that the exacerbated acute GVHD mediated by adoptively transferred donor IL-17-producing CD4 + T cells was associated with enhanced Th1 responses and increased serum levels of Th1 cytokines.
IL-17 alleviates acute GVHD and suppresses Th1 responses
Previous studies have suggested that IL-17 could negatively regulate the differentiation of Th1 cells. 26 To examine whether IL-17 could alleviate acute GVHD by inhibiting Th1 responses, we analyzed the percentages of IFN-γ + CD4 + T cells in the spleen, liver, lungs and IELs. Compared with the recipients of WT donors, we found that the percentages of IFN-γ + CD4 + T cells were significantly increased in the spleens, livers and IELs from the recipients of IL-17 − / − donor cells (Figure 3a) . We confirmed the increased Th1 response in the recipients of IL-17 − / − donor cells by measuring the levels of Tbet expression in CD4 + T cells in target organs (Figure 3b ). The percentages of IFN-γ + CD4 + T cells in the mice that received WT BM/IL-17 − / − splenocytes and the mice that received IL-17 − / − BM/WT splenocytes were between those of the WT and IL-17 − / − donor groups (data not shown). We also observed an increased percentage of IFN-γ + CD8 + T cells in the IELs from the recipients of IL-17 − / − donor cells in comparison with the recipients of WT donor cells (Figure 3c ). The serum levels of IFN-γ were also elevated in the recipients of IL-17 − / − donor cells (Figure 3d ). These data indicated that IL-17 alleviated acute GVHD and suppressed Th1 responses.
Th17 cells are known as the dominate source of IL-17; however, other cells, including CD8 + T cells, γδ T cells and natural killer T cells, could also produce IL-17. To examine which cell subsets are the major IL-17 producers during Figure S2A) . We found that CD4 + T cells were the major IL-17-producing cells in GVHD organs.
GVHD, we analyzed the IL-17 production by different cell populations in GVHD target organs (Supplementary
To further address the protective role of IL-17 in the development of GVHD, lethally irradiated BALB/c mice were transplanted with 1 × 10 7 IL-17 − / − BM and 5 × 10 6 IL-17 − / − spleen cells, followed by treatment with either PBS or rmIL-17 at a dose of 1 μg/mouse on days 0 and 7 post BMT. As shown in Figure 4a , the mice that received rmIL-17 survived significantly longer than the PBS controls (P = 0.024). IL-17 treatment also alleviated the clinical signs of acute GVHD (Figure 4b ) and reduced the damage of GVHD target tissues (Figures 4c and d) . The infiltration of donor CD3 + T cells in the colon was significantly reduced (Figure 4e) . Furthermore, IL-17 treatment decreased the percentages and numbers of IFN-γ + CD4 + T cells in GVHD target tissues (Figure 4f) . The decreased Tbet expression in CD4 + T cells also confirmed the decreased Th1 response induced by IL-17 treatment (Figure 4g) . Interestingly, IL-17 treatment also increased the percentages of CD8 + CD25 + Foxp3 + T cells by more than two-fold in the spleens (Po0.05; Supplementary Figure S3A) , while no significant change in CD4 + CD25 + Foxp3 + T (Treg) cells was observed (data not shown). In addition, the serum levels of IFN-γ were notably reduced by rmIL-17 treatment (Po0.05 Figure 4h ). Collectively, these results suggested that IL-17 alleviated acute GVHD and suppressed Th1 responses. 
IL-17 reduces macrophage infiltration of GVHD target organs
Our previous studies have shown that IL-17 R is highly expressed on myeloid cells, including macrophages and myeloid-derived suppressor cells (MDSCs), and IL-17 may have a direct effect on these cells. 27 Therefore, we examined the myeloid populations in the GVHD target tissues in all three experimental settings. We found that there was no significant difference in the percent of macrophages and DCs in the spleens, livers, lungs and IELs between the recipients of WT CD4 + T cells and IL-17 − / − CD4 + T cells (Figure 5a) . However, the percentages of macrophages in the spleens, livers and IELs from recipients of IL-17 − / − donor cells were significantly increased compared with the recipients of WT donor cells (Figure 5c Adoptive transfer of donor IL-17 − / − CD4 + T cells during BMT prolonged GVHD-related survival compared with WT CD4 + T cells (Figures 1a and b) . This result is consistent with a previous study showing that Th17 cells contributed to CD4-mediated GVHD. 9 Th17 cells have been shown to enhance Th1 cell recruitment by inducing chemokine expression. 28 Th17 cells have also been shown to possess plasticity during the late stages of development; 29, 30 committed Th17 cells can become effector cells that predominantly produce IFN-γ. It has been found in the BMT model that a large number of Th1 cells in the recipient mice originated from donor T cells that were initially skewed toward the Th17 lineage. 31 Our result also showed that the difference in Th1 responses was only present in the transferred donor CD4 + T-cell population. Therefore, the increase in Th1 cells and the augmentation of acute GVHD by the adoptively transferred donor IL-17-producing CD4 + T cells could be due to the transition from Th17 to IFN-γ producers in vivo.
Other T cells, including CD8 + T cells, 32, 33 γδ T cells, 34 and NKT cells, 35, 36 can also produce IL-17A. However, the major IL-17-producing cell subset in GVHD organs is still CD4 + T cells. Infusion with donor WT or IL-17 − / − splenocytes did not affect GVHD-related survival when WT BM was given (Figures 1c and d and Kappel et al. 9 ). However, IL-17 from the splenocytes did provide protection against GVHD when IL-17 − / − BM was transferred during the BMT (Figures 1c  and d) . The difference in GVHD pathogenesis between the IL-17 produced by donor CD4 + T cells and the IL-17 produced by donor splenocytes could be the presence of donor macrophages in the splenocyte population, which we showed to be critical for the protective effect of IL-17. The transferred donor IL-17-producing CD4 + T cells could be influenced by the host inflammatory environment to become IFN-γ-producing cells before they could encounter donor macrophages. On the other hand, when splenocytes were transferred, their IFN-γ production could be reduced by interacting with co-transferred donor We observed decreased Th1 responses in vivo in the presence of donor-derived or exogenous IL-17 ( Figures 3 and 4) . This is consistent with the results of a previous study using IL-17 − / − donors and recombinant IL-17 in a nonmyeloablative allogeneic BMT model. 8 The same study showed that IL-17 may suppress Th1 responses through IL-12-dependent effects on host DCs. We also examined the role of IL-17 on Th1 differentiation in the presence of donor DCs, donor macrophages, host DCs, or host macrophages (Figures 6a-d) . Only donor macrophages could promote Th1 differentiation in the absence of IL-17. We also observed that IL-17 could decrease the percentages of macrophages in the spleen, liver and IELs post BMT (Figures 5c-f) . The discrepancy between our results and the previous study could be due to the different conditioning regimens. We used a single dose of lethal irradiation, which may be different from the sub-lethal irradiation used in that study in terms of the production of inflammatory cytokines, the expression of adhesion molecules, and the activation of donor and host APCs. 37 Although we have clearly shown that IL-17 can suppress Th1 differentiation through donor macrophages and that it is dependent on IL-12 or IFN-γ (Figure 6 ), the detailed mechanism still needs further investigation. IL-17R can be expressed on various myeloid cells. Therefore, IL-17 could function directly on macrophages to suppress IL-12 expression. Our previous study has shown that IL-17 could promote IL-23 production by myeloid-derived suppressor cells 27 and IL-23 could downregulate IL-12 via inhibition of IL-12 p35 and p40 expression. 38 In another study, IL-23 was found to antagonize the IL-12-induced secretion of IFN-γ through IL-12 receptors and reducing STAT4 phosphorylation. 39 Therefore, IL-17 could inhibit IL-12 and IFN-γ production and Th1 differentiation indirectly through IL-23.
In conclusion, this is the first demonstration in the same allogeneic BMT model that adoptively transferred donor IL-17-producing CD4 + T cells augment, but IL-17 alleviates, acute GVHD. Adoptively transferred donor IL-17-producing CD4 + T cells promote, while IL-17 suppresses, Th1 responses, possibly through downregulation of IL-12 production by donor macrophages. Our study provides further evidence for the protective role of IL-17 in acute GVHD. Although Th17 cells have been found to be elevated in acute GVHD patients, [14] [15] [16] their pathological role may not be totally dependent on IL-17, and neutralizing IL-17 may aggravate acute GVHD. Further investigation of the possible therapeutic applications of IL-17 in acute GVHD is warranted.
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